Cara Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel therapeutics for pain and pruritus. Its lead product, KORSUVA, is a treatment for pruritus in patients with chronic kidney disease undergoing hemodialysis, which is currently marketed in the U.S. and has potential for expansion into other geographies and indications.
Cara Therapeutics generates revenue primarily through the sale of KORSUVA, which targets a niche market of patients suffering from chronic kidney disease-related pruritus. The company benefits from a unique formulation that addresses unmet medical needs, providing a competitive edge in a market with limited alternatives.
Regulatory approvals for new indications of KORSUVA
Partnerships or licensing agreements with larger pharmaceutical companies
Clinical trial results for pipeline products
Market adoption rates of KORSUVA in the hemodialysis market
Regulatory changes affecting drug approval processes
Technological disruption in drug development methodologies
Emergence of alternative therapies for pruritus
Potential for larger pharmaceutical companies to enter the market
High cash burn rate impacting liquidity
Limited revenue generation leading to reliance on equity financing
low - The demand for therapeutic drugs like KORSUVA is less sensitive to economic cycles, as healthcare spending tends to remain stable.
Moderate - Higher interest rates could increase the cost of financing for R&D, impacting cash flow and valuation.
minimal - The company has low debt levels, reducing its exposure to credit market fluctuations.
growth - Investors looking for high-risk, high-reward opportunities in biotechnology.
high - The stock has shown significant volatility, with a 1-year return of -80.6%.